Stock BIO3 BIOTEST AG
Add to a list
To use this feature you must be a member
Log inSign up

News Biotest AG

Equities

BIO3

DE0005227235

Market Closed - Xetra
Other stock markets
 16:36:16 26/04/2024 BST 		5-day change 1st Jan Change
28.7 EUR 0.00% Intraday chart for Biotest AG +0.35% -7.42%
04-19 Biotest Launches New Plasma Collection Center in Germany MT
03-28 Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biotest Launches New Plasma Collection Center in Germany
MT
Biotest AG opens 12th plasma collection centre in Germany
EQ
Biotest AG increased sales by 32% in the financial year 2023
EQ
Biotest : Sustainability report Declaration of compliance 2023
PU
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biotest : Invitation / Agenda of Annual General Meeting 2024
PU
Biotest : Notes on agenda item 1 - German Version
PU
Biotest achieves EBIT forecast for 2023
EQ
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
EQ
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
Biotest AG opens 11th plasma collection centre in Germany
EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)
EQ
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
EQ
Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023
EQ
Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024
CI
Biotest AG: Increase of the EBIT guidance
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIO3 Stock
  4. News Biotest AG